-+ 0.00%
-+ 0.00%
-+ 0.00%
Changes in Hong Kong stocks | Peger Biopharmaceutical-B (02565) opened more than 11% and its core product, Paidakang, was successfully included in the 2026 National Health Insurance Catalogue
Share
Listen to the news

The Zhitong Finance App learned that Peger Biopharmaceutical-B (02565) opened more than 11% higher. As of press release, it rose 11.54% to HK$3.625, with a turnover of HK$19.96 million.

According to the news, Peger Biopharmaceuticals announced that the core innovative drug product Vipenatide Injection (trade name: Pidacan®) independently developed by the Group was successfully included in the “2026 National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue” recently announced by the National Health Security Administration.

According to public information, Pidacan is a GLP-1 weekly preparation for blood sugar control in adults with type 2 diabetes. Earlier, Peger and Shanghai Tengrui Pharmaceuticals reached an exclusive commercial cooperation in mainland China and set a goal of cumulative sales exceeding RMB 10 billion. Product sales revenue was confirmed by Peger. This medical insurance access superposition partner's nationwide promotion network is expected to accelerate the release of Pidacang and provide key support for these commercialization goals.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending